<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">There is evidence to suggest that convalescent plasma transfusion from patients who have recovered from the infection with a high neutralizing antibody titer (NAT) may provide short-term passive immunity that could be beneficial in the prevention of infection or as a treatment strategy for patients with COVID-19 [
 <xref ref-type="bibr" rid="CR63">63</xref>â€“
 <xref ref-type="bibr" rid="CR68">68</xref>]. Convalescent plasma has previously been used to improve the survival rate of patients with SARS, Ebola, H1N1, and MERS, all of which showed variable outcomes [
 <xref ref-type="bibr" rid="CR66">66</xref>, 
 <xref ref-type="bibr" rid="CR69">69</xref>, 
 <xref ref-type="bibr" rid="CR70">70</xref>].
</p>
